Evidence map›Paper›PMID 34058059›Full record

ArticleMolecular oncology2022

SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells.

Ka-Kui Chan, Zahi Abdul-Sater, Aditya Sheth, Dana K Mitchell, Richa Sharma, Donna M Edwards, Ying He, Grzegorz Nalepa, Steven D Rhodes, D Wade Clapp and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ka-Kui ChanDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Zahi Abdul-SaterDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-0340-1657
Aditya ShethDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Dana K MitchellDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Richa SharmaDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Donna M EdwardsDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Ying HeDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Grzegorz NalepaDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Steven D RhodesDivision of Pediatric Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
D Wade ClappDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Elizabeth A Sierra PotchanantDepartment of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-0040-5916
Riley Hospital for Children · USIndiana University School of Medicine

Funding

Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASEST32HL007910 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Roland W. Herzog, Reuben Kapur · 1999 to 2026
$7.6M
Postdoctoral Research Training in Pediatric Clinical PharmacologyT32HD069047 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI RENBARGER, JAMIE L · 2011 to 2020
$1.9M
Mitotic failure in Fanconi anemia: mechanisms and role in carcinogenesisR01HL132921 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI CLAPP, DAVID W · 2017 to 2020
$1.8M
Mitotic failure in Fanconi anemia: mechanisms and role in carcinogenesisR56HL132921 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI NALEPA, GRZEGORZ · 2016 to 2016
$390k
Weakened spindle checkpoint in vivo: a cause of aneuploidy and cancer in FA?F30CA200227 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI EDWARDS, DONNA · 2016 to 2017
$77k
NCATS NIH HHS UL1 TR001108NCI NIH HHS F30 CA200227NHLBI NIH HHS R01 HL132921NHLBI NIH HHS R56 HL132921NHLBI NIH HHS T32 HL007910NICHD NIH HHS K12 HD000850NICHD NIH HHS T32 HD069047
6 · The paper itself

Abstract

The Fanconi anemia (FA) pathway safeguards genomic stability through cell cycle regulation and DNA damage repair. The canonical tumor suppressive role of FA proteins in the repair of DNA damage during interphase is well established, but their function in mitosis is incompletely understood. Here, we performed a kinome-wide synthetic lethality screen in FANCA

Indexed as

Fanconi AnemiaCell CycleFanconi Anemia Complementation Group A ProteinFanconi Anemia Complementation Group ProteinsHumansMitosisProtein Serine-Threonine KinasesSynthetic Lethal MutationsFANCA protein, humanFanconi Anemia Complementation Group A ProteinFanconi Anemia Complementation Group ProteinsProtein Serine-Threonine Kinasessalt-inducible kinase-2, humancancerFanconi anemia pathwaySIK2spindle assembly checkpointsynthetic lethality

Identifiers

PMID34058059
PMCPMC8847993
OpenAlexW3165591844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.